BioVentrix Scoops Up CE Mark Approval for Revivent TC

San Ramon, Calif.-based BioVentrix has nabbed CE mark approval for its Revivent TC transcatheter ventricular enhancement system, which is designed to restore the left ventricle. 

The system excludes scarred myocardium from the healthy tissue of the left ventricle to improve cardiac performance and quality of life following a myocardial infarction or heart attack.

BioVentrix specializes in treatment options for congestive heart failure caused by ischemic cardiomyopathy. — Anisa Jibrell